Papiller Tiroid Kanserinde Profilaktik Santral Lenf Nodu Diseksiyonu Kararında Kılavuzlara Uymalı mıyız?

Abstract

Keywords

• Tiroid Kanseri
• Tiroidektomi
• Lenf Nodu Diseksiyonu

Papiller Tiroid Kanserinde Profilaktik Santral Lenf Nodu Diseksiyonu Kararında Kılavuzlara Uymalı mıyız?

Abstract

Objectives: The study aimed to investigate the effectiveness and complication rate of central lymph node dissection in patients with papillary thyroid cancer for whom prophylactic central lymph node dissection (pSLND) is not recommended according to treatment guidelines. Materials and Methods: Ninety-one patients with papillary thyroid cancer who underwent SLND in addition to thyroid surgery performed in a single institution and by a single surgeon were included in the study. The patients were divided into two groups according to the guideline recommendations as SLND recommended (n=42) and pSLND not recommended (n=49). The groups were compared among themselves and also in terms of preoperative and postoperative evaluation results. Results: The findings indicated that patients for whom pSLND was not recommended had a 34.7% rate of central lymph node metastasis. Additionally, 17.9% of all patients had a change in SLND indication in the postoperative evaluation. There was no significant difference in the rate of extrathyroidal extension or capsule invasion between the groups. However, the rate of transient hypoparathyroidism was significantly higher in the SLND recommended group (p=0.032). When the preoperative and postoperative evaluation results of all patients were compared, it was observed that there was a significant difference between multicentricity, capsule and extrathyroidal invasion, and metastatic lymph node counts (p<0.05). Conclusion: In conclusion, it is thought that treatment guideline recommendations should be evaluated in parallel with the volume of centers and surgical experience, so that more pSLND can be applied in patients with cN0 thyroid cancer, with similar complication rates, better locoregional recurrence control, and therefore better disease-free survival and quality of life.

Keywords

• Tiroid Kanseri
• Tiroidektomi
• Lenf Nodu Diseksiyonu

References

1. 1. Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 2022;10:264-272.
2. 2. Zhao W, You L, Hou X, et al. The Effect of prophylactic central neck dissection on locoregional recurrence in papillary thyroid cancer after total thyroidectomy: a systematic review and meta-analysis: pCND for the Locoregional Recurrence of Papillary Thyroid Cancer. Ann Surg Oncol. 2017;24:2189-2198.
3. 3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249.
4. 4. Filetti S, Durante C, Hartl D, et al Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30:1856-1883.
5. 5. Dimov RS. The effect of neck dissection on quality of life in patients withdifferentiated thyroid cancer. Gland Surg. 2013;2:219-226.
6. 6. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133.
7. 7. Pacini F, Basolo F, Bellantone R, et al. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J Endocrinol Invest. 2018;41:849-876.
8. 8. Agrawal N, Evasovich MR, Kandil E, et al. Indications and extent of central neck dissection for papillary thyroid cancer: An American Head and Neck Society Consensus Statement. Head Neck. 2017;39:1269-1279.

9. 9. Mitchell AL, Gandhi A, Scott-Coombes D, et al. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130:S150-S160.
10. 10. Dolidze DD, Shabunin AV, Mumladze RB, et al. A narrative review of preventive central lymph node dissection in patients with papillary thyroid cancer - a necessity or an excess. Front Oncol. 2022;12:906695.
11. 11. Deutschmann MW, Chin-Lenn L, Nakoneshny SC, et al. Practice patterns among thyroid cancer surgeons: implications of performing a prophylactic central neck dissection. J Otolaryngol Head Neck Surg. 2016;45:55.
12. 12. Parvathareddy SK, Siraj AK, Ahmed SO, et al. Risk factors for central lymph node metastases and benefit of prophylactic central lymph node dissectionin middle eastern patients with cN0 papillary thyroid carcinoma. Front Oncol. 2021;11:819824.
13. 13. Calo PG, Conzo G, Raffaelli M, et al. Total thyroidectomy alone versus ipsilateral versus bilateral prophylactic central neck dissection in clinically node-negative differentiated thyroid carcinoma. A retrospective multicenter study. Eur J Surg Oncol. 2017;43:126-132.
14. 14. Dobrinja C, Troian M, Cipolat Mis T, et al. Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a singlecenter.Int J Surg. 2017;41(Suppl 1):S40-S47.
15. 15. Lang BH, Ng SH, Lau LL, et al. A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. Thyroid. 2013;23:1087-1098.
16. 16. Hughes DT, Rosen JE, Evans DB, et al. Prophylactic central compartment neck dissection in papillary thyroid cancer and effect on locoregional recurrence. Ann Surg Oncol. 2018;25:2526-2534.
17. 17. Nylen C, Eriksson FB, Yang A, et al. Prophylactic central lymph node dissection informs the decision of radioactive iodine ablation in papillary thyroid cancer. Am J Surg. 2021;221:886-892.
18. 18. Conzo G, Tartaglia E, Avenia N, et al. Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends. World J Surg Oncol. 2016;14:149.
19. 19. Sippel RS, Robbins SE, Poehls JL, et al. A Randomized controlled clinical trial: no clear benefit to prophylactic central neck dissection in patients with clinically node negative papillary thyroid cancer. Ann Surg. 2020;272:496- 503.
20. 20. Song JL, Li LR, Xu ZL, et al. Long-Term survival in patients with papillary thyroid cancer who did not undergo prophylactic central lymph node dissection: A SEER-based study. World J Oncol. 2022;13:136-144.
21. 21. Sun R, Sheng J, Zhou Y, et al. Relationship between the extent of central node dissection and parathyroid function preservation in thyroid cancer surgery. Gland Surg. 2021;10:1093-1103.
22. 22. Stubljar B, Pastorcic Grgic M, Mayer L, et al. Elective central compartment lymph node dissection does not increase the risk of postoperative hypoparathyroidism in patients treated for differentiated thyroid cancer. Acta Clin Croat. 2020;59(Suppl 1):115-121.
23. 23. Sancho JJ, Lennard TW, Paunovic I, et al. Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399:155-163.